NeoPharm Further Refines Cost Structure and Reviews Strategy for Pipeline Development

WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (NASDAQ:NEOL) today provided an update on its efforts to further refine the Company’s cost structure and strategy for pipeline development. As a result of continued cost reduction initiatives, NEOPHARM has decreased its annualized operating cash consumption rate to approximately $5 million, exclusive of clinical development and legacy costs of the Company’s pipeline.

Back to news